Tom Pike

The Centre for Digital Life Norway transforms Norwegian biotechnology research and education to increase innovation and value creation for society. The centre has research projects all over the country. Transdisciplinary collaboration is our trademark.

Inven2 is the largest technology transfer office in the Nordic region. We are responsible for: - Commercialization of innovations from our owners - Administration and financial follow up of clinical trials - Administration of Research fund Inven2’s goal is to make research benefit society and to contribute to value creation. Inven2 is owned by the University of Oslo and Oslo University Hospital.

We are an early stage pharmaceutical development company focused on the development of menaquinone-7 (MQ-7) for the treatment of vascular and other tissue calcification-related diseases. Our Mission: To develop a novel and potentially groundbreaking therapy to help patients prevent and reverse vascular calcification. Vascular calcification and arterial stiffening are a driving factors in MACE (major adverse cardio events) and are implicated in multiple conditions and diseases. There is, as of today, no available therapy to directly address calcification-related arterial stiffness. A recent clinical study stated that end-stage renal disease patients are 50x more likely to suffer from cardiovascular disease than the general population. CKD affects millions of patients across the world, and its occurrence is expected to significantly increase in the coming decades. In aortic stenosis, calcification is often the primary cause or complicating factor. It is an issue affecting millions of patients. Arteriosclerosis is a disease impacting tens of millions of patients, and once again calcification is believed to play a role. In all these diseases, the process of vascular calcification and arterial stiffening is increasingly being recognized as a major factor driving further complications and medical procedures, and putting a burden on healthcare systems likely measured in the billions of dollars. The ability to prevent, and potentially reverse, calcification and arterial stiffening across these various disease conditions would indeed be a game-changing therapy. Kaydence Pharma believes this is possible, and we believe that MQ-7 has the potential to help improve medical outcomes, increase the quality of life and potentially avoid expensive, high-risk procedures for millions of patients.

Vectron is your partner for development of robust and cost-efficient microbial protein production processes. Using our proprietary portfolio of expression technologies, we develop bacterial strains that produces your protein at right titers and with right quality.

The Centre for Digital Life Norway transforms Norwegian biotechnology research and education to increase innovation and value creation for society. The centre has research projects all over the country. Transdisciplinary collaboration is our trademark.

Inven2 is the largest technology transfer office in the Nordic region. We are responsible for: - Commercialization of innovations from our owners - Administration and financial follow up of clinical trials - Administration of Research fund Inven2’s goal is to make research benefit society and to contribute to value creation. Inven2 is owned by the University of Oslo and Oslo University Hospital.

We are an early stage pharmaceutical development company focused on the development of menaquinone-7 (MQ-7) for the treatment of vascular and other tissue calcification-related diseases. Our Mission: To develop a novel and potentially groundbreaking therapy to help patients prevent and reverse vascular calcification. Vascular calcification and arterial stiffening are a driving factors in MACE (major adverse cardio events) and are implicated in multiple conditions and diseases. There is, as of today, no available therapy to directly address calcification-related arterial stiffness. A recent clinical study stated that end-stage renal disease patients are 50x more likely to suffer from cardiovascular disease than the general population. CKD affects millions of patients across the world, and its occurrence is expected to significantly increase in the coming decades. In aortic stenosis, calcification is often the primary cause or complicating factor. It is an issue affecting millions of patients. Arteriosclerosis is a disease impacting tens of millions of patients, and once again calcification is believed to play a role. In all these diseases, the process of vascular calcification and arterial stiffening is increasingly being recognized as a major factor driving further complications and medical procedures, and putting a burden on healthcare systems likely measured in the billions of dollars. The ability to prevent, and potentially reverse, calcification and arterial stiffening across these various disease conditions would indeed be a game-changing therapy. Kaydence Pharma believes this is possible, and we believe that MQ-7 has the potential to help improve medical outcomes, increase the quality of life and potentially avoid expensive, high-risk procedures for millions of patients.

Vectron is your partner for development of robust and cost-efficient microbial protein production processes. Using our proprietary portfolio of expression technologies, we develop bacterial strains that produces your protein at right titers and with right quality.